A Phase I Study of Merestinib Monotherapy or in Combination With Other Anti-Cancer Agents in Japanese Patients With Advanced and/or Metastatic Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Merestinib (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 16 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Feb 2017 Status changed from not yet recruiting to recruiting.
- 01 Feb 2017 Planned End Date changed from 1 May 2018 to 4 Jun 2018.